Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Co. Ltd. have jointly disclosed new nucleoside prodrugs reported to be useful for the treatment of cancer.
A Boehringer Ingelheim Pharma GmbH & Co. KG patent describes new phenylpiperidine derivatives acting as glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors.
Hyundai Pharmaceutical Co. Ltd. has patented probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
Researchers at University of Oxford have been awarded funding by Cancer Research UK to develop a vaccine to prevent ovarian cancer. The team will receive up to £600,000 (US$784,000) for the study over the next 3 years to support lab research on Ovarianvax.
Dark genome miner Enara Bio Ltd. has closed a $32.5 million series B that will see the lead program targeting the first of a novel class of cancer antigens it has discovered through to the clinic. Enara calls these cancer antigens “dark antigens” (the name is trademarked). It says they can be found in solid tumors irrespective of the immune phenotype, and are often expressed at high prevalence across multiple different tumors.
Nutshell Biotech (Shanghai) Co. Ltd. has identified nitrogen-containing macrocyclic compounds acting as DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.
Scientists at CeMM-Forschungsinstitut für Molekulare Medizin GmbH and Max Planck Society for the Advancement of Science EV have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 11 (DCAF11) binding moiety covalently linked to a different protein targeting moiety through a linker.
Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are widely used in cancer immunotherapy, but poor tissue distribution or immune-related adverse events often limit their application.
At this week’s American Society for Radiation Oncology meeting, scientists from The University of Texas MD Anderson Cancer Center reported the discovery and preclinical evaluation of CD47-LLO, a novel microbial-inspired antibody-drug conjugate (ADC) for the treatment of cancer.
RSS
